Video
Dr. Spigel Discusses Results from a Phase III Study Exploring Eribulin in NSCLC
Author(s):
David Spigel, MD, director of Lung Cancer Research at the Sarah Cannon Research Institute, discusses results from a phase III study exploring eribulin for the treatment of patients with non-small cell lung cancer.
David Spigel, MD, director of Lung Cancer Research at the Sarah Cannon Research Institute, discusses results from a phase III study exploring eribulin for the treatment of patients with non-small cell lung cancer.
The two arms on this trial were similar — about 40% of patients on both arms were Asian. Most patients received gemcitabine or docetaxel.
The primary endpoint on this trial, overall survival, was not improved. Progression-free survival and response rates were similar between the two arms.
<<<
View more from the 2014 Multidisciplinary Symposium in Thoracic Oncology
Latest CME
View All
(CME Track) Clinical Consultations™: Framing a New Approach to Geographic Atrophy Management – Expert Insights into Recent Developments
Apr 23rd 2025 - Apr 24th 2026
Optimizing Today and Looking to Tomorrow in Metastatic CRPC—Homing in on EZH2
Apr 23rd 2025 - Apr 24th 2026
Addressing Unmet Needs in HER2+ Metastatic BTC
Apr 18th 2025 - Apr 19th 2026
.png?fit=crop&auto=format)
